CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced the addition of Mr. Richard Wallace to the Company’s Board of Directors. Mr. Wallace has more than thirty years of experience in strategic product development and commercialization gained at leading healthcare companies and is currently a Senior Vice President of Research and Development at GlaxoSmithKline.
